No Detail Found!

Response of Induction Therapy in Different Immmunological Subtypes of Acute Lymphoblastic Leukemia in Children.

Author(s)
Muhammad Ihtesham Khan Department of Pathology, Khyber Medical College, Peshawar - Pakistan
Nuzhat Yasmeen Department of Oncology, Pakistan Institute of Medical Sciences, Islamabad - Pakistan
Sunia Arif Khan Department of Pathology, Khyber Medical College, Peshawar - Pakistan
SalimUr Rahman Department of Medicine, Khyber Teaching Hospital, Peshawar - Pakistan
Abstract
Objective: To analyse response of induction chemotherapy in different immunological subtypes of acute lymphoblastic leukemia in children. Material and Methods: This cross sectional study was conducted at the Department of Pathology, Pakistan Institute of Medical Sciences (P.I.M.S), Islamabad, Pakistan from June 2014 to September 2015. A total of 51 children ranging from 1-13 years of age, and diagnosed with ALL were included in the study. Immunophenotyping was recorded. All patients were given chemotherapy according to the BFM (Berlin-Frankfurt-Münster) protocol in the Oncology Department P.I.M.S. During induction therapy, 10 patients died. Remaining 41 patients received a complete course of induction therapy. Response to induction therapy was determined in these 41 patients by counting blast cells in the bone marrow at the end of induction therapy. Patients having 5% blast cells are said to be in remission failure. Remisson pattern was used to assess the response of induction chemotherapy in different immunophenotypes of ALL and conclusions were drawn accordingly. Results: Out of 51 patients , 10 patients died during induction therapy. Remaining 41 patients received complete course of induction therapy. These 41 patients were analysed for response of induction therapy. Out of 41 patients, there were 27 (65.9%) males and 14 (34.1%) females. Out of 41 patients of ALL, 36 (87.8%) patients had Precursor B-cell ALL, 3 (7.3%) patients had T-cell ALL, while 2 (4.8%) patients had Precursor T-cell ALL. So, 36 (87.8%) patients had B-lineage ALL, while 5 (12.2%) patients had T-lineage ALL. Out of 41 patients, 37 (90%) patients showed complete remission at the end of induction therapy, while 4 (10%) patients were not in complete remission. Out of 36 patients of Precursor B-cell ALL, 33 (91.7%) were in complete remission, while 3 (8.3%) were not in remission. There were 2 patients of Precursor T-cell ALL and both of them achieved complete remission. There were 3 patients of T-cell ALL. Two of them achieved complete remission, while 1 faced induction failure. Out of 10 patients who died during induction therapy, 5 (50%) patients died due to intracranial bleeding, and 4 (40%) patients died due to sepsis. Tumor lysis syndrome was observed in 1 (10%) patient. Bleeding was the common cause of death. Conclusions: The present study showed that response to induction therapy is better in Precursor B-cell ALL as compared to T-cell ALL. It was also found that the rates of complete remission are lower in our setup. Induction death rate is high in our setup due to delayed platelet and blood transfusions, poor socioeconomic status,and lack of knowledge about the disease in population.
Publication Details
Page(s) 28-32
DOI DOI not available
Published Journal: Journal of Medical Science, Volume: 26, Issue: 1, Year: 2018

Request the full text from PASTIC

References
CooperSL,BrownPA, 2015.Treatment of pediatric acute lymphoblastic leukemia,Pediatr Clin North Am 62 61 -73
GrigoropoulosNF,PetterR,VeerMB,ScottMA,FollowsGA, .diagnosis and management,BMJ. 2013 Mar 28 f1660 -
.,doi: 10 -
McGregorS,McNeerJ,GurbuxaniS. Beyond, 2012.the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia,Semin Diagn Pathol 29 2 -11
2011., 224 -33
Wiemels J., .Perspectives on the causes of childhood leukemia,Chem Biol Interact. 2012 Apr 5 59 -67
ZuckermanT,RoweJM, .Pathogenesis and prognostication in acute lymphoblastic leukemia,F1000 Prime Rep. 2014 Jul 10 59 -
eCollection, 2014., -
., 10 -
., 63 1399 -404
AsifMJ,IqbalZ,MalikA,HayeeA, 2000.Trends in childhood acute leukaemia: Six year experience at Shaikh Zayed Hospital Lahore, 24 43 -49
IkramN,HassanK,RamzanM,TufailS,BukhariK., 2003.Leukemias in children,J Pak Inst Med Sci 14 728 -34
KhawajaMR,AllanaSS,AkbaraliAN,AdilSN,KhurshidM,Pervez S, 2005.Flow cytometric and demographic analysis of T cell acute Lymphoblastic Leukemia in Pakistani population,J Ayub Med Coll Abbottabad 17 3 -8
YasmeenN,AshrafS., .Childhood acute lymphoblastic leukaemia; epidemiology and clinicopathological features,J Pak Med Assoc 59 150 -53
InabaH,GreavesM,MullighanCG, .Acute lymphoblastic leukaemia,Lancet. 2013 Jun 1 1943 -55
HungerSP,LuX,DevidasM,CamittaBM,GaynonPS,WinickNJ, .Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group,J Clin Oncol. -
BassanR,HoelzerD., .Modern therapy of acute lymphoblastic leukemia,J Clin Oncol.2011 Feb 10 532 -43
PuiCH,MullighanCG,EvansWE,RellingMV, .Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?,Blood. 2012 Aug 9 1165 -74
BartramCR,SchrauderA,KöhlerR,SchrappeM., .Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment,Dtsch Arztebl Int 109 652 -58
SchrappeM,HungerSP,PuiCH,SahaV,GaynonPS,BaruchelA, .Outcomes after induction failure in childhood acute lymphoblastic leukemia,2012 Apr 366 1371 -81
PaganinM,FerrandoA, .Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia,Blood Rev. 2011Mar 25 83 -90
KhalidS,MoizB,AdilSN,KhurshidM., .Retrospective review of pediatric patients with acute lymphoblastic leukemia: a single center experience,Indian J Pathol Microbiol 53 704 -10
IdrisM,FaridJ,SarwarJ,AhmedS,WiqarMA,BadshaS., 2010.Response rate of Pakistani children with acute lymphoblastic leukaemia to Medical Research Council acute lymphoblastic leukaemia 97 chemotherapy protocol,J Ayub Med Coll Abbottabad 22 8 -11
PuiCH,EvansWE, .Treatment of Acute Lymphoblastic Leukemia,2006 Jan 12 166 -78
StaryJ,ZimmermannM,CampbellM,CastilloL,DibarE,DonskaS, .Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002,J Clin Oncol. 2014 Jan 20 174 -84
LautenM,MorickeA,BeierR,ZimmermannM,StanullaM,MeissnerB, .Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia,Haematologica 97 1048 -56
KonjaJ,RajićL,AničićM,HajnžićF,ČulićS,SmokvinaM,BatinićD., 2004.Pediatric blood & cancer., 43 432 -
ChoudhryVP,KrishnamurthyL,AryaLS,DesaiN,PatiH, 1992.Causes of mortality in children with acute lymphocytic leukemia,Indian Pediatr 29 709 -13
SeifAE,FisherBT,LiY,TorpK,RheamDP,HuangYS, .Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia,Pediatric blood & cancer 61 846 -52
SilvermanLB,StevensonKE,O'BrienJE,AsselinBL,BarrRD,ClavellL, 1985.Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (, 24 320 -34
0

Citations

0

Downloads

44

Views